Ozempic became a cultural phenomenon almost overnight. Celebrities, social media, and news headlines made it the most talked-about weight loss development in decades. But fixating on one brand name has left millions of people with an incomplete picture of what’s actually available — and what doctors are actually prescribing.
There are now nine injectable options in the weight loss conversation, each with a different mechanism, dosing schedule, side effect profile, and level of clinical evidence. Some are approved specifically for weight loss. Others are diabetes medications being used off-label with significant results. One is poised to outperform everything currently available.
Here is the complete, clear guide — what each one does, what the side effects look like, and which one physicians currently reach for most.
How These Injections Work
Most injectable weight loss medications belong to a class called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It signals the pancreas to release insulin, tells the liver to reduce glucose production, and — critically for weight loss — sends satiety signals to the brain that reduce appetite and slow gastric emptying.
When you inject a GLP-1 agonist, you’re essentially keeping that “I’m full” signal switched on for much longer than food alone would. The result: reduced hunger, smaller portions, fewer cravings, and measurable weight loss — without requiring willpower.
Newer medications add additional hormonal targets, making them significantly more powerful. Here are all nine.
The 9 Injectable Weight Loss Options
1. Semaglutide — Wegovy
FDA-approved specifically for chronic weight management in 2021, Wegovy is the gold standard injectable for non-diabetic weight loss. It’s administered once weekly via pen injector and works by mimicking GLP-1 to suppress appetite and reduce caloric intake.
Clinical trials show an average weight loss of 15–17% of body weight over 68 weeks — results unprecedented in the history of non-surgical weight management. It is currently the most prescribed injectable for weight loss in patients without diabetes.
2. Semaglutide — Ozempic
Same active molecule as Wegovy, different approved indication. Ozempic is FDA-approved for type 2 diabetes management but is widely prescribed off-label for weight loss — particularly when insurance coverage for Wegovy is unavailable. The dosing differs slightly, and the maximum approved dose for Ozempic is lower than Wegovy, which may produce modestly less weight loss in some patients.
The supply shortages and cost controversies surrounding Ozempic stem largely from its off-label use in the weight loss population outpacing its original diabetes supply chain.
3. Tirzepatide — Zepbound
The newest FDA-approved weight loss injection (approved 2023) and currently the most effective available. Zepbound is a dual agonist — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously, producing a more powerful appetite suppression and metabolic effect than GLP-1 alone.
Clinical trials showed average weight loss of 20–22% of body weight at the highest dose — making it the most effective pharmaceutical weight loss option in history, short of bariatric surgery. Once weekly injection. This is increasingly the first choice for physicians when coverage allows.
4. Tirzepatide — Mounjaro
The diabetes-approved version of tirzepatide, prescribed off-label for weight loss in the same way Ozempic is used outside its approved indication. Identical molecule to Zepbound, with comparable weight loss outcomes in practice. Often prescribed when Zepbound coverage is unavailable but Mounjaro coverage exists under a diabetes diagnosis.
5. Liraglutide — Saxenda
The original FDA-approved injectable for weight loss, approved in 2014. Saxenda requires daily injection rather than weekly — a significant compliance disadvantage compared to newer options. Average weight loss in trials was approximately 8–9% of body weight, notably lower than semaglutide or tirzepatide.
Still prescribed for patients who don’t tolerate weekly injectables, those for whom newer medications are contraindicated, or in healthcare systems where newer options aren’t yet accessible. Its longer safety record is considered an advantage by some physicians in specific patient populations.
6. Liraglutide — Victoza
The diabetes-approved formulation of liraglutide, used off-label for weight loss. Daily injection, similar outcomes to Saxenda. Largely being replaced in clinical practice by more effective weekly options but remains available and covered for patients with type 2 diabetes.
7. Dulaglutide — Trulicity
A once-weekly GLP-1 receptor agonist approved for type 2 diabetes that produces modest but meaningful weight loss — typically 3–5% of body weight — as a secondary benefit. Not approved for weight loss and not as effective as semaglutide or tirzepatide for that purpose, but frequently prescribed for diabetic patients who experience beneficial weight reduction alongside glucose control.
The autoinjector pen is notably easy to use, which improves adherence for patients who are anxious about injections.
8. Exenatide — Byetta and Bydureon BCise
The oldest GLP-1 agonist in clinical use. Byetta requires twice-daily injection, while Bydureon BCise is a once-weekly extended-release formulation. Both produce modest weight loss — approximately 2–4% of body weight — and are rarely initiated as new prescriptions today given the superior efficacy of newer agents.
Still used by long-term patients who are stable on the medication and by physicians managing patients with specific tolerability profiles or drug interaction concerns that preclude newer options.
9. Retatrutide — Investigational Triple Agonist
Not yet FDA-approved but generating significant clinical attention. Retatrutide is a triple hormone agonist — targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials published in the New England Journal of Medicine showed average weight loss of approximately 24% of body weight over 48 weeks — the highest ever recorded in a pharmaceutical weight loss trial.
If Phase 3 trials confirm these results and FDA approval follows (anticipated in the next few years), retatrutide would represent another generational leap in injectable weight loss medicine.
Side Effects: What to Expect
The GLP-1 class shares a common side effect profile across all medications, with intensity varying by agent and individual tolerance:
Most common (affecting 30–50% of users):
- Nausea — typically worst during dose escalation, improves significantly after 4–8 weeks
- Vomiting — less common than nausea, usually manageable
- Diarrhea or constipation — often alternating, particularly in early weeks
- Reduced appetite beyond intended levels — occasionally leading to inadequate caloric intake
Less common but important:
- Fatigue during dose escalation periods
- Mild injection site reactions — redness, itching, or bruising
- Hair loss (telogen effluvium) — related to rapid calorie reduction rather than the medication directly
- Acid reflux or belching
Serious but rare:
- Pancreatitis — patients with personal or family history of pancreatitis should use with caution
- Gallstones — rapid weight loss increases gallstone formation risk regardless of method
- Diabetic retinopathy worsening — specific concern in diabetic patients on semaglutide
- Thyroid C-cell tumors — observed in rodent studies; patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use GLP-1 agonists
The much-discussed “Ozempic face” — facial volume loss giving a gaunt appearance — is not a medication side effect but a consequence of rapid overall fat loss. It occurs with any significant weight loss and can be mitigated by slowing the pace of weight reduction.
Which One Do Doctors Prefer Most?
Among physicians actively prescribing for weight loss, tirzepatide (Zepbound/Mounjaro) has rapidly become the preferred first-line choice when insurance coverage is available — its superior efficacy at 20–22% weight loss surpasses semaglutide’s 15–17% with a comparable tolerability profile.
For patients where tirzepatide isn’t covered or accessible, semaglutide (Wegovy/Ozempic) remains the most prescribed and most evidence-backed alternative.
The choice between specific brand names often comes down to insurance coverage, cost, and individual patient factors rather than clinical preference — the active molecules are what matter most.
What These Medications Are Not
Injectable weight loss medications are not permanent solutions used in isolation. Clinical guidelines are consistent: they work best alongside dietary changes, physical activity, and behavioral support. Stopping the medication without establishing sustainable lifestyle habits typically results in significant weight regain — studies show patients regain two-thirds of lost weight within one year of discontinuation.
They are powerful tools. Like all tools, their outcome depends entirely on how they’re used.
The Bottom Line
The weight loss injection landscape has transformed more in the past five years than in the previous five decades. From daily injections with modest results to weekly pens producing surgical-level weight loss, the options available today are genuinely remarkable — and the pipeline suggests they will continue improving.
If injectable weight loss therapy is something you’re considering, the conversation starts with your doctor — armed now with the full picture, not just the brand name everyone’s heard of.
Found this helpful? Share it with someone navigating the overwhelming world of weight loss options — clarity makes better decisions possible.
